PORTFOLIO NEWS Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO January 15, 2024 Read More » NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need January 9, 2024 Read More » Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 Read More » ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones January 8, 2024 Read More » Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases January 8, 2024 Read More » Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease January 3, 2024 Read More » Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing January 3, 2024 Read More » Kimia Therapeutics Raises $55 Million Series A December 19, 2023 Read More » Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics December 19, 2023 Read More » Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting December 11, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO January 15, 2024 Read More »
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need January 9, 2024 Read More »
Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 Read More »
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones January 8, 2024 Read More »
Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases January 8, 2024 Read More »
Remix Therapeutics™ Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease January 3, 2024 Read More »
Remix Therapeutics™ Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing January 3, 2024 Read More »
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics December 19, 2023 Read More »
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting December 11, 2023 Read More »
